Actor Eric Dane visited Washington, D.C., pressing lawmakers to reauthorize the ACT for ALS, a federal program that supports research and access to investigational therapies for amyotrophic lateral sclerosis. The 52-year-old joined patient advocates from I AM ALS on Tuesday, Sept. 30, as Congress faces a tight calendar and a long list of health funding decisions.
Dane, known for roles on television dramas, framed the urgency in human terms. In a video shared by California Rep. Eric Swalwell, he said, “ALS is the last thing they want to diagnose anybody with.” His message was aimed at keeping support in place as patients and families seek more treatment options and speedier research.
Why ACT for ALS Matters
ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. About 5,000 people in the United States are diagnosed each year, and an estimated 30,000 people live with the condition. Most patients face a life expectancy of two to five years after diagnosis.
The Accelerating Access to Critical Therapies for ALS Act became law in 2021. It authorized up to $100 million per year through 2026 for two main goals: to fund research into neurodegenerative diseases and to expand access to investigational treatments outside of clinical trials for patients who qualify.
Supporters say the program helps link federal research with patient needs. It also offers a structured path to “expanded access,” which can be a lifeline when no approved treatments meet a patient’s condition.
A Renewed Push On Capitol Hill
Dane’s visit added celebrity visibility to a movement largely led by patients and caregivers. I AM ALS, co-founded by advocates Brian Wallach and Sandra Abrevaya, has spent years organizing constituents, meeting with lawmakers, and building bipartisan support for ALS funding.
“ALS is the last thing they want to diagnose anybody with.” — Eric Dane, in a video posted by Rep. Eric Swalwell
Lawmakers from both parties backed the original legislation, citing an urgent need for better science and faster pathways to promising therapies. With the initial authorization window ending in 2026, advocates want Congress to move on a reauthorization to avoid gaps and signal long-term commitment to research.
Progress, Setbacks, And Unmet Needs
Approved treatments for ALS remain limited. Riluzole and edaravone can slow disease progression for some patients, but neither offers a cure. In 2024, Amylyx Pharmaceuticals withdrew its ALS drug Relyvrio after a trial failed to confirm earlier benefits, a reminder of the high bar for success and the stakes for patients.
Researchers are testing gene-targeted approaches and novel mechanisms, while care teams continue to refine respiratory and nutritional support that can extend and improve life. Advocates argue that ACT for ALS funds help move such ideas from labs to patients more quickly.
- Research: Grants support projects on biomarkers, trial design, and new targets.
- Access: A federal pilot helps some patients receive investigational drugs outside trials.
- Data: Programs encourage sharing results to inform future treatments.
Funding Debates And Policy Questions
Congress faces competing budget pressures, which could affect the size and scope of any reauthorization. Some policy analysts raise concerns that expanded access may reduce clinical trial enrollment if patients opt for investigational drugs outside studies. Patient groups counter that carefully designed access programs can run alongside trials and still generate useful safety and outcomes data.
Public health advocates also point to lessons from other diseases. Structured access programs can provide real-world evidence, guide dosing strategies, and help identify which patients are most likely to benefit, while maintaining trial integrity.
What To Watch Next
Reauthorization efforts will hinge on bipartisan negotiations in key committees and the broader budget process. Advocates plan further meetings with staff and members, aiming to lock in multiyear funding to avoid disruptions in ongoing research and access initiatives.
Dane’s appearance reflects a growing push to keep ALS on the legislative agenda. The next steps include drafting bill language, securing co-sponsors, and aligning with appropriators who control actual spending. Patients and families will watch closely for signs of momentum, especially as the current authorization approaches its end date.
The latest advocacy puts a human face on a disease that still lacks a cure. The central question for Congress is whether to sustain and strengthen a program designed to move faster from discovery to care. The answer will shape research plans, patient access, and the pace of progress over the next several years.
